Insider Transactions in Q1 2025 at Inari Medical, Inc. (NARI)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Robert Keith Warner Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
12,149
-100.0%
|
-
|
|
Feb 19
2025
|
Catherine M. Szyman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,429
-100.0%
|
-
|
|
Feb 19
2025
|
Thomas Tu Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
478,767
-100.0%
|
-
|
|
Feb 19
2025
|
Thomas Tu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,406
+1.52%
|
-
|
|
Feb 19
2025
|
Jonathan D Root Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
335
-100.0%
|
-
|
|
Feb 19
2025
|
Jonathan D Root Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
541,149
-100.0%
|
-
|
|
Feb 19
2025
|
Karen Silva Principal Accounting Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,719
-100.0%
|
-
|
|
Feb 19
2025
|
Kevin T Strange Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
67,502
-100.0%
|
-
|
|
Feb 19
2025
|
Dana G Mead Jr. Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,148
-100.0%
|
-
|
|
Feb 19
2025
|
Donald B Milder Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,831,714
-100.0%
|
-
|
|
Feb 19
2025
|
Donald B Milder Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
259,126
-100.0%
|
-
|
|
Feb 19
2025
|
William Hoffman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
238,987
-100.0%
|
-
|
|
Feb 19
2025
|
Andrew Hykes President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
717,637
-100.0%
|
-
|
|
Feb 19
2025
|
Andrew Hykes President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,393
+2.76%
|
-
|
|
Feb 19
2025
|
Andrew Hykes President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,650
-100.0%
|
-
|
|
Feb 19
2025
|
Cynthia L Lucchese Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
38,429
-100.0%
|
-
|
|
Feb 19
2025
|
Rebecca Chambers Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
9,684
-100.0%
|
-
|
|
Feb 10
2025
|
Andrew Hykes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
194,538
+8.09%
|
$389,076
$2.45 P/Share
|
|
Feb 10
2025
|
Thomas Tu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
148,004
+12.46%
|
$444,012
$3.46 P/Share
|
|
Feb 04
2025
|
Kevin T Strange Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,102
+23.82%
|
-
|
|
Feb 04
2025
|
Andrew Hykes President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
67,282
+11.8%
|
-
|
|
Feb 04
2025
|
Karen Silva Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,504
+27.22%
|
-
|
|
Feb 04
2025
|
Thomas Tu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,102
+6.13%
|
-
|
|
Jan 06
2025
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
200,000
-25.96%
|
$12,000,000
$60.7 P/Share
|
|
Jan 01
2025
|
Andrew Hykes President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,409
-0.25%
|
$224,859
$51.05 P/Share
|
|
Jan 01
2025
|
William Hoffman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,246
-0.25%
|
$114,546
$51.05 P/Share
|
|
Jan 01
2025
|
Thomas Tu Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,303
-0.19%
|
$117,453
$51.05 P/Share
|
|
Jan 01
2025
|
Kevin T Strange Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,037
-0.37%
|
$52,887
$51.05 P/Share
|